CHT102 for mesothelin-positive advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must be advanced or metastatic and have the mesothelin marker.
- You must have tried at least one standard treatment, or there is no standard first-line treatment for your cancer type.
- You must be in fairly good health, with a performance status of 0 or 1.
- You must have at least one measurable tumor spot on scans.
- You cannot be pregnant or breastfeeding, and you must agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CHT102 for people with advanced pancreatic cancer that has a specific protein (mesothelin) on their tumor cells. It's for those who have already tried standard treatments without success or couldn't tolerate them.
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
This trial tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have a specific protein (B7-H3). The goal is to see if these modified immune cells can shrink tumors or slow their growth.
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
Hear when a new Mesothelin Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.